IDT and Aldevron launch research-grade Cas9 mRNA for CRISPR genome editing

Danaher companies Integrated DNA Technologies (IDT) and Aldevron, have launched research-grade S.p. Cas9 mRNA in wild-type and SpyFi™ high-fidelity formats. The offering is available to researchers and therapeutic developers for CRISPR-based genome editing workflows, providing performance, format flexibility and manufacturing continuity to help advanced gene editing programs progress from research toward development with greater confidence.

Combining CRISPR engineering and mRNA manufacturing expertise

The co-developed offering combines IDT’s CRISPR protein engineering expertise with Aldevron’s mRNA manufacturing capabilities. It is designed to support efficient genome editing, reduce off-target risk and provide greater continuity as gene editing programs advance.

As gene editing moves toward clinically relevant ex vivo and in vivo applications, researchers need CRISPR mRNA reagents that provide reproducible editing performance, reduce technical risk, support emerging delivery methods and fit programs that may ultimately require scale-up.

IDT and Aldevron address these requirements through optimized Cas9 mRNA constructs manufactured in consistent research-grade formats, with a path to scaled CGMP-manufactured versions as programs progress.

Supporting translational gene editing across multiple cell types

The Cas9 mRNA offering is designed to support high on-target editing efficiency across multiple cell types, including T cells, induced pluripotent stem cells (iPSCs) and immortalized cells. The SpyFi high-fidelity format helps reduce the risk of off-target editing.

The mRNA formats are compatible with electroporation, cationic lipids and lipid nanoparticles (LNPs), allowing researchers to select the delivery approach that best fits their CRISPR genome editing application.

Enzymatic capping simplifies access

The Cas9 mRNA is enzymatically capped, offering a high-performing alternative to certain proprietary capping technologies. By reducing licensing burden and simplifying access, the offering is intended to help researchers concentrate on advancing their science rather than managing licensing complexity.

Creating a connected path from CRISPR discovery to development

The launch adds Cas9 mRNA to the broader IDT and Aldevron gene editing workflow. It expands the options available to customers seeking reliable research tools, scientific support and continuity across CRISPR design, analysis, RNA manufacturing and future scale-up.

This Cas9 mRNA launch is the first in a planned suite of co-developed offerings from IDT and Aldevron. Base editors and prime editors are slated for later this year.

Building on their history of supplying tools and manufacturing support for genomic medicine workflows, IDT and Aldevron are providing a new mRNA modality for Cas9-based gene editing. The solution combines IDT’s guide RNA design and analysis expertise with Aldevron’s mRNA manufacturing capabilities to streamline the progression of Cas9 gene editing programs from early research through CGMP manufacturing.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>